HIV, lenacapavir and Hetero Drugs
Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has been testing it as an injectable form ...
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an ...
Gilead Sciences Inc. (GILD) announced that additional data from its pivotal Phase 3 PURPOSE 2 trial demonstrated a 96% reduction in ...
Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing ...
The twice yearly lenacapavir injection will be available in 120 countries with a series of regulatory filings beginning by ...
We welcome Gilead’s statement of commitment to non-profit pricing, but we had been waiting eagerly for a specific price. We ...
7 October 2024 (Lima, Peru) – New data from the PURPOSE 2 study of twice-yearly lenacapavir for HIV prevention are among the scientific highlights at HIVR4P 2024, the 5th HIV Research for Prevention ...
Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India ...
US pharma giant Gilead Sciences' partnership with domestic companies to produce generic versions of its groundbreaking HIV ...